alosetron Lotronex restricted
Selected indexed studies
- Pharmacology and clinical experience with alosetron. (Expert Opin Investig Drugs, 2000) [PMID:11060667]
- Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. (Expert Rev Gastroenterol Hepatol, 2010) [PMID:20136586]
- Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. (Clin Ther, 2008) [PMID:18555935]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pharmacology and clinical experience with alosetron. (2000) pubmed
- Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. (2010) pubmed
- Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. (2008) pubmed
- FDA approves restricted marketing of Lotronex. (2002) pubmed
- Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder. (2003) pubmed
- Management of the irritable bowel syndrome. (2001) pubmed
- Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? (2004) pubmed
- Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. (2010) pubmed
- [Irritable bowel syndrome: current treatment options]. (2007) pubmed
- Treatment of abdominal pain in irritable bowel syndrome. (2014) pubmed